Pulmonary hypertension owing to lung disease and/or hypoxia

This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…

This study tests an inhaled drug called frespaciguat (MK-5475) in 129 adults who have high blood pressure in their lungs caused by COPD. The main goal is to see if the drug helps people walk farther in 6 minutes after 24 weeks compared to a placebo. Participants take one daily in…

This study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…

This phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…

This study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve fu…

This study is collecting blood samples from 550 adults with different types of pulmonary hypertension to measure two proteins, Activin-A and FSTL3. Researchers want to see if these proteins can predict who will need a lung transplant or die within two years. The goal is to find a…